Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease

Metabolic-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease worldwide. However, its pathophysiological mechanism is complicated, and currently, it has no FDA-approved pharmacological therapies. In recent years, mesenchymal stem cell (MSC) therapy has attracted...

Full description

Saved in:
Bibliographic Details
Main Authors: Sitong Yi, Qingwei Cong, Ying Zhu, Qiumin Xu
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2023/3919002
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552893114220544
author Sitong Yi
Qingwei Cong
Ying Zhu
Qiumin Xu
author_facet Sitong Yi
Qingwei Cong
Ying Zhu
Qiumin Xu
author_sort Sitong Yi
collection DOAJ
description Metabolic-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease worldwide. However, its pathophysiological mechanism is complicated, and currently, it has no FDA-approved pharmacological therapies. In recent years, mesenchymal stem cell (MSC) therapy has attracted increasing attention in the treatment of hepatic diseases. MSCs are multipotent stromal cells that originated from mesoderm mesenchyme, which have self-renewal and multipotent differentiation capability. Recent experiments and studies have found that MSCs have the latent capacity to be used for MAFLD treatment. MSCs have the potential to differentiate into hepatocytes, which could be induced into hepatocyte-like cells (HLCs) with liver-specific morphology and function under appropriate conditions to promote liver tissue regeneration. They can also reduce liver tissue injury and reverse the development of MAFLD by regulating immune response, antifibrotic activities, and lipid metabolism. Moreover, several advantages are attributed to MSC-derived exosomes (MSC-exosomes), such as targeted delivery, reliable reparability, and poor immunogenicity. After entering the target cells, MSC-exosomes help regulate cell function and signal transduction; thus, it is expected to become an emerging treatment for MAFLD. In this review, we comprehensively discussed the roles of MSCs in MAFLD, main signaling pathways of MSCs that affect MAFLD, and mechanisms of MSC-exosomes on MAFLD.
format Article
id doaj-art-0ab4b414d4ed489ab5ed254c4a401bd9
institution Kabale University
issn 1687-9678
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Stem Cells International
spelling doaj-art-0ab4b414d4ed489ab5ed254c4a401bd92025-02-03T05:57:25ZengWileyStem Cells International1687-96782023-01-01202310.1155/2023/3919002Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver DiseaseSitong Yi0Qingwei Cong1Ying Zhu2Qiumin Xu3Department of Infectious Disease and Liver Disease Center of Integrated Traditional Chinese and Western MedicineDepartment of Infectious Disease and Liver Disease Center of Integrated Traditional Chinese and Western MedicineDepartment of Infectious Disease and Liver Disease Center of Integrated Traditional Chinese and Western MedicineThe First Affiliated Hospital of Dalian Medical UniversityMetabolic-associated fatty liver disease (MAFLD) is currently the most common chronic liver disease worldwide. However, its pathophysiological mechanism is complicated, and currently, it has no FDA-approved pharmacological therapies. In recent years, mesenchymal stem cell (MSC) therapy has attracted increasing attention in the treatment of hepatic diseases. MSCs are multipotent stromal cells that originated from mesoderm mesenchyme, which have self-renewal and multipotent differentiation capability. Recent experiments and studies have found that MSCs have the latent capacity to be used for MAFLD treatment. MSCs have the potential to differentiate into hepatocytes, which could be induced into hepatocyte-like cells (HLCs) with liver-specific morphology and function under appropriate conditions to promote liver tissue regeneration. They can also reduce liver tissue injury and reverse the development of MAFLD by regulating immune response, antifibrotic activities, and lipid metabolism. Moreover, several advantages are attributed to MSC-derived exosomes (MSC-exosomes), such as targeted delivery, reliable reparability, and poor immunogenicity. After entering the target cells, MSC-exosomes help regulate cell function and signal transduction; thus, it is expected to become an emerging treatment for MAFLD. In this review, we comprehensively discussed the roles of MSCs in MAFLD, main signaling pathways of MSCs that affect MAFLD, and mechanisms of MSC-exosomes on MAFLD.http://dx.doi.org/10.1155/2023/3919002
spellingShingle Sitong Yi
Qingwei Cong
Ying Zhu
Qiumin Xu
Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease
Stem Cells International
title Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease
title_full Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease
title_fullStr Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease
title_full_unstemmed Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease
title_short Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease
title_sort mechanisms of action of mesenchymal stem cells in metabolic associated fatty liver disease
url http://dx.doi.org/10.1155/2023/3919002
work_keys_str_mv AT sitongyi mechanismsofactionofmesenchymalstemcellsinmetabolicassociatedfattyliverdisease
AT qingweicong mechanismsofactionofmesenchymalstemcellsinmetabolicassociatedfattyliverdisease
AT yingzhu mechanismsofactionofmesenchymalstemcellsinmetabolicassociatedfattyliverdisease
AT qiuminxu mechanismsofactionofmesenchymalstemcellsinmetabolicassociatedfattyliverdisease